Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 8/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 8/20 | 0.37 |
| ▸ | KHK | P50053 | 1/20 | 0.35 |
| ▸ | XDH | P47989 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.31 |
| ▸ | CUL4A | Q13619 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16092200 | 0.78 | TRPV4 (0.42) | TRPV4CYP11B1CYP11B2EGLN2 | |
| SCHEMBL2657089 | 0.75 | TRPV4 (0.39) | TRPV4CYP11B1CYP11B2KHKKDM4E | |
| SCHEMBL4478973 | 0.75 | CYP11B2 (0.40) | TRPV4CYP11B1CYP11B2KHK | |
| SCHEMBL15577745 | 0.74 | CA1 (0.31) | ALDH1A1 | |
| SCHEMBL17651309 | 0.74 | TRPV4 (0.42) | TRPV4CYP11B1CYP11B2KHKKDM4E | |
| SCHEMBL28597079 | 0.74 | KDM4E (0.43) | TRPV4CYP11B1CYP11B2XDHKDM4E | |
| SCHEMBL30352797 | 0.74 | KDM4E (0.43) | TRPV4CYP11B1CYP11B2XDHKDM4E | |
| SCHEMBL26697124 | 0.73 | KHK (0.42) | TRPV4CYP11B1CYP11B2KHKXDH | |
| SCHEMBL15421833 | 0.72 | AR (0.42) | TRPV4CYP11B1CYP11B2 | |
| SCHEMBL19876132 | 0.70 | ALDH1A1 (0.39) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101778849-A | Fused quinoline derivatives useful as gaba modulators | ASTRAZENECA AB | 2010-07-14 | — | — | CN | disclosed |
| EP-2176263-A2 | FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS | AstraZeneca AB (SE) | 2010-04-21 | — | — | EP | disclosed |
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| WO-2008155572-A2 | FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS | ASTRAZENECA AB (SE) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | COMT, BACE1, BDNF | TRPV4 4304/4885CYP11B1 406/4885CYP11B2 381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.